Blood Cancer Talks cover image

Blood Cancer Talks

Latest episodes

undefined
Mar 26, 2025 • 50min

Episode 58: CAR Transgenic T-cell Lymphoproliferative Neoplasms (CTTLN) with Dr. Piers Blombery

In this episode, we explore the emerging entity of CAR Transgenic T-cell Lymphoproliferative Neoplasms (CTTLN), a rare but important complication of CAR T-cell therapy. Dr. Piers Blombery from Peter MacCallum Cancer Center joins us to dissect two cases from the CARTITUDE-4 trial where patients developed T-cell lymphomas expressing the chimeric antigen receptor following cilta-cel treatment for multiple myeloma. As a bonus, we also briefly discussed Dr. Blombery’s paper on menin inhibitors in UBTF tandem duplicated AML. Here are the papers we discussed: 1. CTTLN cases from CARTITUDE-4: https://pubmed.ncbi.nlm.nih.gov/39938094/2. CTTLN case from MSKCC with insertional mutagenesis: https://pubmed.ncbi.nlm.nih.gov/39908432/3. Other CTTLN cases in myeloma: https://pubmed.ncbi.nlm.nih.gov/38865661/https://pmc.ncbi.nlm.nih.gov/articles/PMC8417502/4. Response and resistance to menin inhibitors in UBTF tandem duplication AML: https://pubmed.ncbi.nlm.nih.gov/38924737/
undefined
Mar 19, 2025 • 55min

Episode 57. ASH 2024 Update on Leukemia/Myeloid Neoplasms with Dr. Jayastu Senapati

In this episode, we delve into the key clinically relevant abstracts in leukemia and myeloid neoplasms with Dr. Jayastu Senapati from the MD Anderson Cancer Center. Here are the links to the abstracts we discussed: Older AML: Ven+HMA vs 7+3Abstract 450: https://ash.confex.com/ash/2024/webprogram/Paper210320.htmlAbstract 971: https://ash.confex.com/ash/2024/webprogram/Paper202801.htmlAbstract 969: https://ash.confex.com/ash/2024/webprogram/Paper199267.htmlVenetoclax resistance mechanismshttps://pubmed.ncbi.nlm.nih.gov/39478230/FLAG-GO vs FLAG-IDA https://ashpublications.org/blood/article/144/Supplement%201/1513/532742/Gemtuzumab-Ozogamicin-Added-to-Fludarabine CPX-351: Abstract 55: https://ash.confex.com/ash/2024/webprogram/Paper207094.htmlAbstract 60: https://ash.confex.com/ash/2024/webprogram/Paper200413.htmlMenin Inhibitors Abstract 211 https://ash.confex.com/ash/2024/webprogram/Paper194384.htmlAbstract 212 https://ash.confex.com/ash/2024/webprogram/Paper207106.htmlAbstract 213 https://ash.confex.com/ash/2024/webprogram/Paper194827.htmlAbstracts 214 https://ash.confex.com/ash/2024/webprogram/Paper198218.htmlAbstract 215 https://ash.confex.com/ash/2024/webprogram/Paper198218.htmlAbstract 216 https://ash.confex.com/ash/2024/webprogram/Paper204375.html FLT3 inhibitors Abstract 221: https://ash.confex.com/ash/2024/webprogram/Paper201595.html MDS Abstract 349: https://ash.confex.com/ash/2024/webprogram/Paper194510.html ATRA in MDS:  https://ash.confex.com/ash/2024/webprogram/Paper200433.html  
undefined
Feb 12, 2025 • 1h 3min

Episode 56. Management of Newly Diagnosed CML with Dr. Hagop Kantarjian

In this episode, we discuss the management of CML with Dr. Hagop Kantarjian from MD Anderson Cancer Center. Here are the key articles we discussed:  1. ASC4FIRST RCT: Asciminib in newly diagnosed CML. https://pubmed.ncbi.nlm.nih.gov/38820078/ 2. 5-year follow-up of ENESTnd RCT (nilotinib): https://pubmed.ncbi.nlm.nih.gov/26837842/ 3. 10-year follow-up of ENESTnd RCT (nilotinib): https://pubmed.ncbi.nlm.nih.gov/33414482/ 4. 10-year follow-up of CML-IV RCT (imatinib): https://pubmed.ncbi.nlm.nih.gov/25676422/ 5. MD Anderson data on low-dose dasatinib (50 mg): https://pubmed.ncbi.nlm.nih.gov/36054032/https://pubmed.ncbi.nlm.nih.gov/31553487/ 6. CML: 2025 update on diagnosis, therapy, and monitoring: https://pubmed.ncbi.nlm.nih.gov/39093014/ 
undefined
37 snips
Jan 11, 2025 • 38min

Episode 55. ASH 2024 Myeloma Updates with Dr. Rakesh Popat

Dr. Rakesh Popat, a consultant hematologist and associate professor at UCL, shares insights from ASH 2024 on myeloma and amyloidosis. He discusses the AQUILA trial, highlighting daratumumab's benefits for high-risk smoldering multiple myeloma. The conversation also covers the promising early data of Anito-Cel, a novel CAR T therapy, and updates on survival outcomes for cilta-cel in relapsed myeloma. Additionally, he reviews long-term advancements in treatment strategies for AL amyloidosis and ultra-high-risk myeloma patients.
undefined
12 snips
Dec 22, 2024 • 58min

Episode 54. ASH 2024 Lymphoma and CLL Highlights with Dr. David Russler-Germain

Dr. David A Russler-Germain, a lymphoma clinician scientist from Washington University, shares insights on groundbreaking lymphoma and CLL research from ASH 2024. They delve into the promising results of the TRIANGLE trial for mantle cell lymphoma, highlighting significant survival gains with ibrutinib. The discussion also covers the efficacy of Tafasitamab in follicular lymphoma and the impressive response rates for Longcast Tuximab Tessarine. Additionally, they evaluate new treatment strategies for CLL and the implications for patient care.
undefined
Nov 13, 2024 • 45min

Episode 53. Belantamab Makes a Comeback with Dr. Hang Quach

In this episode, we discuss the comeback of belantamab mafadotin in multiple myeloma with Dr. Hang Quach, along with some other important abstracts presented at EHA/ASCO 2024. Here are the studies we discussed: 1. DREAMM-7 RCT: Belantamab-Vd vs Daratumumab-Vd in relapsed MM. https://pubmed.ncbi.nlm.nih.gov/38828933/2. DREAMM-8 RCT: Belantamab-Pd vs PVd in relapsed MM. https://pubmed.ncbi.nlm.nih.gov/38828951/3. Long-term follow-up of CASSIOPEIA Trial: https://pubmed.ncbi.nlm.nih.gov/38889735/4. Update on MRD data from PERSEUS Trial: https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.7502
undefined
Oct 26, 2024 • 42min

Episode 52. Management of Hodgkin Lymphoma in Older Adults with Dr. Andrew Evens

In this episode, we dive into the management of older adults with Hodgkin Lymphoma with Dr. Andrew Evens. Here are the key articles we discussed: 1. Comparison of ABVD versus Stanford V in older Hodgkin Lymphoma patients: https://pmc.ncbi.nlm.nih.gov/articles/PMC3906856/2. Outcome of older adults ECHELON-1: https://pubmed.ncbi.nlm.nih.gov/34162178/3. Sequential BV-AVD in older adults with Hodgkin Lymphoma: https://pubmed.ncbi.nlm.nih.gov/30179569/4. SWOG S1826 trial (Nivo-AVD vs AAVD in advanced stage classical HL): https://pubmed.ncbi.nlm.nih.gov/39413375/5. S1826 outcomes in older adults: https://ash.confex.com/ash/2023/webprogram/Paper180114.html6. Single-agent BV for older adults with Hodgkin: https://ashpublications.org/blood/article/142/Supplement%201/4435/503453 
undefined
69 snips
Sep 27, 2024 • 57min

Episode 51. Venetoclax in AML with Dr. Andrew Wei

Dr. Andrew Wei, a leading expert in acute myeloid leukemia from the Peter McCallum Cancer Center, discusses the innovative use of venetoclax in treating AML. He highlights groundbreaking clinical trials that have transformed treatment pathways, particularly for older patients. Innovative therapies like venetoclax combined with hypomethylating agents are explored, along with ongoing resistance challenges and the role of genetic mutations in personalized treatment. The conversation also touches on the implications of minimal residual disease negativity in enhancing patient outcomes.
undefined
Aug 29, 2024 • 42min

Episode 50. Quadruplets in Newly Diagnosed Transplant-Ineligible Myeloma with Dr. Timothy Schmidt

In this episode, we discuss the management of newly diagnosed transplant in-eligible multiple myeloma with Dr. Timothy Schmidt, with a special focus on IMROZ and BENEFIT RCTs testing quadruplets in this space. Here are the key papers we discussed: 1. MAIA trial (Daratumumab-Lenalidomide-Dexamethasone [DRd] vs Rd in newly diagnosed transplant ineligible myeloma): https://pubmed.ncbi.nlm.nih.gov/34655533/2. S0777 trial (VRd vs Rd in newly diagnosed myeloma [transplant-ineligible or transplant-deferred]): https://pubmed.ncbi.nlm.nih.gov/32393732/3. IMROZ trial (Isatuximab-VRd vs VRd in newly diagnosed transplant-ineligible myeloma): https://pubmed.ncbi.nlm.nih.gov/38832972/4. IFM-2020/BENEFIT trial (Isatuximab-VRd vs Isatuximab-Rd in newly diagnosed transplant-ineligible myeloma): https://pubmed.ncbi.nlm.nih.gov/38830994/5. GEM2017FIT trial (VMP-Rd vs KRd vs Dara-KRd in newly diagnosed transplant-ineligible myeloma): https://ashpublications.org/blood/article/142/Supplement%201/209/500199 
undefined
Aug 14, 2024 • 43min

Episode 49. Updates on Low-Risk MDS with Dr. Maximilian Stahl

In this episode, we discuss updates on low-risk MDS with Dr. Maximilian Stahl with a focus on imetelstat and luspatercept. Here are the trials we discussed: 1. IWG 2019 response criteriahttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7042664/ 2. MEDALIST trial: Luspatercepthttps://www.nejm.org/doi/10.1056/NEJMoa1908892?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed 3. COMMANDS trial : Luspatercept https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00874-7/abstracthttps://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00203-5/abstract 4. IMerge trial: Imetelstat https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01724-5/abstract  

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
App store bannerPlay store banner
🤯 How amazing is this app?!
Sophie
App Store
Snipd helps me keep track of everything I resonated with from a show. I can always find my snips, listen to them again, share them. And there are so many great product updates regularly! Like the feature to chat with the episode: I can retrieve even more knowledge from an episode 🥹 I’m in love with this app 🤍
Best podcast app
JD Stuart
App Store
I’ve been using Snipd for about a year and this app has been life changing. I listen to about 17 hours of podcasts a week and I want to take notes on 95% of them. Snipd makes it so easy to do. I can triple click my headphones and record a snip. The app also improves rapidly which is welcomed. It’s an easy subscription for me to pay.